Cardiff, United Kingdom – 15 July 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today announces the appointment of Douglas E. Williams, Ph.D. as independent Chair of its Board of Directors. He takes over from Ruth McKernan, who retains her role on the Board as a Director and Interim Chief Executive Officer (CEO).
SAN FRANCISCO, July 8, 2025 /PRNewswire/ -- Welsh, Carson, Anderson & Stowe ("WCAS"), a leading private equity firm with a 45-year track record of building...